Loading...

CRVO CERVOMED INC Expansion Plans 8-K Filing

CRVM

CRV

CERVOMED INC

(CRVO)

2026 8-K

Investor Presentation Update

Clinical Trial Update

Financial Results Announced

Phase 1 Study Completion

Drug Inclusion Announcement

Investor Presentation Update

New Biomarker Data

Financial Results Update

FDA Feedback Received

Director Appointment

Investor Presentation Update

Business Update

Equity Offerings

Management Changes

Clinical Trial Update

Financial Results

Investor Update

Clinical Trial Update

Investor Update

Clinical Trial Update

Investor Presentation

FDA Designation

Partnership Announcement

Treatment Announcement

Clinical Trial Update

Sales Agreement Termination

Conference Announcement

Financial Results

Regulation FD Disclosure

Event Announcement

Annual Meeting of Stockholders

Earnings Press Release

Corporate Presentation

Earnings Press Release

Private Placement

Annual Stockholders Meeting

Presentation of Biomarker Data

Amendment to Pre-Funded War...

Appointment of Joshua S. Bo...

Employment Agreements

Conference Presentation

Investor Conferences

Regulation FD Disclosure

Employment Agreement with J...

Earnings Press Release

Appointment of Director

Resignation of Director

Publication and Presentation

Merger and Name Change

Merger and Clinical Trial A...

Merger Proposal

Supplemental Disclosures

Merger Agreement

Appointment of Director

Appointment of Principal Fi...

Departure of CFO

Merger Agreement

Merger Agreement and Confer...

Merger Agreement

Reduction in Force and Depa...

External Links:

On March 4, 2026, CervoMed Inc. announced that it successfully completed a Phase 1 study for neflamapimod, its lead drug candidate, as part of preparation for a planned Phase 3 trial for dementia with Lewy bodies.

AI Assistant

CERVOMED INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.